IN2014DN09450A - - Google Patents

Info

Publication number
IN2014DN09450A
IN2014DN09450A IN9450DEN2014A IN2014DN09450A IN 2014DN09450 A IN2014DN09450 A IN 2014DN09450A IN 9450DEN2014 A IN9450DEN2014 A IN 9450DEN2014A IN 2014DN09450 A IN2014DN09450 A IN 2014DN09450A
Authority
IN
India
Prior art keywords
rivaroxaban
intermediates
preparation
present
provides processes
Prior art date
Application number
Inventor
Pankaj Kumar Singh
Mohammed Salman Hashmi
Yoginder Pal Sachdeva
Chandra Has Khanduri
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN9450DEN2014 priority Critical patent/IN2014DN09450A/en
Publication of IN2014DN09450A publication Critical patent/IN2014DN09450A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention provides processes for the preparation of rivaroxaban and its intermediates.
IN9450DEN2014 2012-04-16 2013-04-16 IN2014DN09450A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN9450DEN2014 IN2014DN09450A (en) 2012-04-16 2013-04-16

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1174DE2012 2012-04-16
PCT/IB2013/053025 WO2013156936A1 (en) 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof
IN9450DEN2014 IN2014DN09450A (en) 2012-04-16 2013-04-16

Publications (1)

Publication Number Publication Date
IN2014DN09450A true IN2014DN09450A (en) 2015-07-17

Family

ID=48539327

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9450DEN2014 IN2014DN09450A (en) 2012-04-16 2013-04-16

Country Status (6)

Country Link
US (1) US20150299160A1 (en)
EP (1) EP2838897A1 (en)
AU (1) AU2013250801A1 (en)
IN (1) IN2014DN09450A (en)
SG (1) SG11201406623PA (en)
WO (1) WO2013156936A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103819468A (en) * 2013-12-05 2014-05-28 浙江天宇药业股份有限公司 Synthesis method of Rivaroxaban and intermediate thereof
IN2014MU00072A (en) 2014-01-08 2015-08-21 Wockhardt Ltd
CN104478820B (en) * 2014-12-22 2016-08-31 杭州瀚康生物医药科技有限公司 A kind of preparation method of Rivaroxaban intermediate
CN104910141B (en) * 2015-05-12 2018-11-02 浙江天顺生物科技有限公司 A kind of preparation method of the chloro- N- of Rivaroxaban intermediate 5- (2- oxiranylmethyl radicals) -2- thenoyl amines
CN104788444B (en) * 2015-05-12 2018-11-06 浙江天顺生物科技有限公司 The preparation method of razaxaban
CN104817550B (en) * 2015-05-26 2017-06-16 山东铂源药业有限公司 A kind of preparation method of razaxaban
CN108707080B (en) * 2018-06-20 2022-01-25 上海圣赢生物科技有限公司 Environment-friendly synthesis method of linezolid and intermediate thereof
CN109400577B (en) * 2019-01-07 2021-01-19 石药集团中奇制药技术（石家庄）有限公司 Rivaroxaban related compound and preparation method and application thereof
CN112110910B (en) * 2019-06-19 2024-03-19 上海特化医药科技有限公司 Method for preparing rivaroxaban intermediate and method for preparing rivaroxaban from rivaroxaban intermediate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101353313A (en) 1997-11-07 2009-01-28 法玛西雅厄普约翰美国公司 Process to produce oxazolidinones
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
DE10300111A1 (en) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide
DE10322469A1 (en) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclic compounds
DE102006051625A1 (en) 2006-11-02 2008-05-08 Bayer Materialscience Ag Combination therapy of substituted oxazolidinones
DE102007028320A1 (en) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituted oxazolidinones and their use
DE102007032347A1 (en) 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl prodrugs
DE102007032345A1 (en) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl prodrugs
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
CN102584738B (en) 2011-01-07 2015-04-29 浙江九洲药业股份有限公司 New technology for synthesizing rivaroxaban intermediate
WO2013046211A1 (en) * 2011-09-27 2013-04-04 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof

Also Published As

Publication number Publication date
AU2013250801A1 (en) 2014-11-06
WO2013156936A1 (en) 2013-10-24
SG11201406623PA (en) 2014-11-27
US20150299160A1 (en) 2015-10-22
EP2838897A1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
MX2022000026A (en) Antibodies to tau.
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX2013015311A (en) Pcsk9-binding polypeptides and methods of use.
MX342240B (en) Anti-fgfr4 antibodies and methods of use.
IN2015DN00127A (en)
JO3466B1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2015006324A (en) Methods for the manufacture of proteolytically processed polypeptides.
IN2014DN09450A (en)
MX2014004022A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
MX2014002053A (en) Anti-mcsp antibodies.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
IN2012MU03723A (en)
MX354303B (en) Anti-biotin antibodies and methods of use.
IN2013MU00848A (en)
MX2015002487A (en) Process for the preparation of teneligliptin.
IN2015DN01688A (en)
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
IN2014DN10209A (en)
IN2013MU01113A (en)
MX337610B (en) Processes for the preparation of (r)-2-acetamido-n-benzyl- 3-methoxypropionamide and intermediates thereof.
MX2015012902A (en) Synthesis of ent-progesterone and intermediates thereof.
IN2013MU03768A (en)
ES2421810A2 (en) Intermediates useful for the synthesis of fexofenadine, processes for their preparation and for the preparation of fexofenadine
IN2013CH05395A (en)